Early-stage VC slump persists, but biotech is a bright spot


The biotech sector accounted for $580 million in investment across six deals last quarter, second only to AI and machine learning.

Previous Cleveland Clinic, Canon to build imaging research center
Next CVS sues US gov't over $400 million tax dispute